



ABN 53 075 582 740

ASX ANNOUNCEMENT
24 March 2021

Change of Company Secretary

Bionomics Limited (ASX: BNO) (**Bionomics** or **Company**), with much sadness advises that Mr Jack Moschakis, Bionomics' Legal Counsel and Company Secretary, passed away on 23 March 2021.

The Bionomics Board of Directors wish to acknowledge Jack's unquestionable commitment, contribution, professionalism and work ethic to Bionomics, its employees and shareholders. Since joining Bionomics in 2015, Jack has been instrumental in the success of many projects. He was highly respected and an integral part of the Bionomics team who will be deeply missed.

Our heartfelt condolences to his wife Nicole, and their children Natalie, Phillip and extended family.

Mr. Adrian Hinton has been appointed as interim Company Secretary.

For the purpose of ASX Listing Rule 12.6, Mr. Adrian Hinton will be the person responsible for communications between the Company and ASX.

This announcement was authorised on behalf of the Board of Bionomics by Errol B. De Souza, Executive Chairman of Bionomics.

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Adrian Hinton
Bionomics Limited
31 Dalglish St,
Thebarton, South Australia
+61 8 8354 6100
ahinton@bionomics.com.au

About Bionomics Limited

Bionomics Limited (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.